Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2018-03-13 Legal Proceedings Report
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
MorphoSys Reports Updated Data from L-MIND Study of MOR208 plus Lenalidomide in Aggressive Lymphoma (r/r DLBCL) (news with additional features)
Legal Proceedings Report Classification · 99% confidence The document is a news release dated March 13, 2018, originating from MorphoSys AG, disseminated via DGAP (a service often used for regulatory news). The content primarily reports updated clinical trial data (L-MIND study results for MOR208) and discusses ongoing discussions with the FDA regarding potential expedited regulatory submission. This type of announcement, focusing on clinical trial updates, scientific data, and regulatory progress, is characteristic of an announcement rather than a formal periodic report (like 10-K or IR). Since it is a press release announcing scientific/development progress and does not fit neatly into specific financial reporting categories (like ER, AR, or DIV), it falls best under the general 'Regulatory Filings' category (RNS) as a broad corporate/regulatory announcement, or potentially an Investor Presentation (IP) if it were structured as slides, but given the format and source (DGAP News), RNS is the most appropriate fallback for non-standard, material corporate news releases.
2018-03-13 English
MorphoSys Presents Results for Fiscal Year 2017 (news with additional features)
Earnings Release Classification · 100% confidence The document explicitly states, "MorphoSys Presents Results for Fiscal Year 2017" and provides detailed financial figures (Revenues, EBIT, R&D expenses) for the full year 2017, along with a financial and operational outlook for 2018. The presence of a detailed financial table summarizing key figures for the fiscal year ending December 31, 2017, strongly indicates a comprehensive annual financial report. Although it is presented as a news release (DGAP-News) announcing these results and mentioning a conference call, the core content is the full-year financial performance summary, which aligns best with the Annual Report (10-K) definition, even if it's an early release or summary thereof. Since the text contains the actual detailed financial results for the entire fiscal year, it is classified as the Annual Report (10-K) rather than just a Report Publication Announcement (RPA). FY 2017
2018-03-13 English
Invitation to Year-End Results 2017 Conference Call
Report Publication Announcement Classification · 99% confidence The document is an 'Invitation to Year-End Results 2017 Conference Call' scheduled for March 13, 2018. It explicitly states that MorphoSys AG 'will publish its Annual Financial Results 2017 on March 13, 2018' and then provides details for the conference call to present these results. This document is an announcement about the upcoming release of the full annual results and the subsequent call, not the full Annual Report (10-K) itself. Since it announces the publication of a major report and provides details for accessing the presentation/call, it fits best under Report Publication Announcement (RPA). It is not the full 10-K, nor is it just an Earnings Release (ER) which usually contains the key figures immediately. The document's primary function is to announce the timing and logistics of the results presentation.
2018-03-08 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' under German securities law (WpHG). It details changes in voting rights percentages held by Baillie Gifford & Co and its subsidiaries, crossing or reaching specific thresholds. This directly corresponds to the definition of a Major Shareholding Notification.
2018-03-06 English
Invitation to Year-End Results 2017 Conference Call
Report Publication Announcement Classification · 99% confidence The document is titled "Invitation to Year-End Results 2017 Conference Call" and explicitly states that MorphoSys AG "will publish its Annual Financial Results 2017 on March 13, 2018." The content focuses entirely on inviting recipients to a conference call to discuss these results, providing dates, times, and dial-in numbers. This is not the full Annual Report (10-K) or the Earnings Release (ER) itself, but rather an announcement about an upcoming event where the results will be discussed. Since the primary purpose is to announce the details of a corporate event (the conference call) related to financial results, it fits best under the category of a Call Transcript (CT) if the transcript were present, or more accurately, an announcement leading up to the results discussion. However, given the options, this document is an invitation/announcement for a call that will discuss the results. If the document were the actual transcript, it would be CT. If it were the initial press release of the results, it would be ER. Since it is an invitation to the call where the results will be presented, and it is short and announces the publication of the results, it strongly aligns with the function of announcing an upcoming event related to financial reporting. The closest fit among the provided options for an announcement about a results presentation/call, especially when the actual results document is not attached, is often related to the earnings process. Given the options, and recognizing this is an invitation to the call where the results will be presented, it is most closely related to the Earnings Release (ER) process, or potentially a Regulatory Filing (RNS) if it were purely administrative. However, because it is specifically about the conference call for the Year-End Results, and the document is short (5034 chars) and serves as a notice, it functions as a precursor to the main financial disclosure. In many databases, such an invitation is classified alongside the earnings announcement. Since the document is an invitation to the conference call where the results will be presented, and it is not the transcript itself, the most appropriate classification related to the earnings cycle is ER, or if we strictly follow the 'Menu vs Meal' rule for short announcements, it could be RPA/RNS. Given that it announces the *event* for the results, and not just the *publication* of a report, I will classify it as related to the Earnings Release (ER) process, as it sets the stage for the official results disclosure. If the document was purely about the *timing* of the release, RPA would fit. Since it's about the *call* to discuss the results, ER is the most contextually relevant financial event code.
2018-03-01 English
MorphoSys Announces That Tremfya(R) (Guselkumab) Data Demonstrated Long-Term Skin Clearance In Patients With Moderate-To-Severe Plaque Psoriasis (news with additional features)
Regulatory Filings Classification · 95% confidence The document is titled 'News Details' and begins with 'Corporate | 20 February 2018 07:30'. It announces study results regarding a drug (Tremfya) and references a press release from a licensee (Janssen). The text structure, use of DGAP-News headers, and the nature of the content (announcing study data presented at a medical meeting) strongly indicate this is a corporate news release or press release, rather than a formal regulatory filing like a 10-K, IR, or a specific financial report. Since it is a general corporate announcement disseminated via a news service (DGAP), and it doesn't fit the specific categories like ER (Earnings Release), DIV (Dividend Notice), or CAP (Financing Update), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements and news releases that don't fit elsewhere, especially when disseminated through official channels like DGAP.
2018-02-20 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.